You are here

Chugai

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

BioSpace

Flag link:

Roche's Chugai pays Halozyme $25M to access subcutaneous delivery tech

Roche's Chugai pays Halozyme $25M to access subcutaneous delivery tech

Fierce Biotech

subcutaneous drug delivery

Haolzyme Therapeutics

Flag link:

After Alexion buyout, AstraZeneca pays Roche $775M to settle Ultomiris patent brawl

After Alexion buyout, AstraZeneca pays Roche $775M to settle Ultomiris patent brawl

Fierce Pharma

Flag link:

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Endpoints

Flag link:

7 drugs likely to hit $1B in annual revenue in the next 5 years

7 drugs likely to hit $1B in annual revenue in the next 5 years

Beckers Hospital Review

Mirati Therapeutics

Flag link:

Chugai’s Enspryng receives regulatory approval from FDA for neuromyelitis optica spectrum disorder

Chugai’s Enspryng receives regulatory approval from FDA for neuromyelitis optica spectrum disorder

Pharmaceutical Business Review

Flag link:

Verastem pens KRAS-focused drug licensing deal with Chugai

Verastem pens KRAS-focused drug licensing deal with Chugai

Fierce Biotech

Flag link:

Roche's Chugai claims Alexion co-opted its patented tech in building Ultomiris

Roche's Chugai claims Alexion co-opted its patented tech in building Ultomiris

Fierce Pharma

Flag link:

Roche's Chugai to set up new $1B+ lab in Yokohama, consolidating R&D

Roche's Chugai to set up new $1B+ lab in Yokohama, consolidating R&D

Endpoints

Flag link:

Lilly Licenses Chugai Pharma's Oral Diabetes Drug for $50 Million Upfront

Lilly Licenses Chugai Pharma's Oral Diabetes Drug for $50 Million Upfront

BioSpace

type 2 diabetes

Flag link:

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

Endpoints

Flag link:

Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai

Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai

Fierce Biotech

atopic dermatitis

Flag link:

Patent Claims To Xtandi Seem Weak

Patent Claims To Xtandi Seem Weak

Seeking Alpha

Flag link:

Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi

Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi

Seeking Alpha

Flag link:

As PhII data looms, Chugai inks a $205M stem cell deal with Athersys

As PhII data looms, Chugai inks a $205M stem cell deal with Athersys

Fierce Biotech

Flag link:

Chugai pours $374M into its Singapore R&D shop

Chugai pours $374M into its Singapore R&D shop

Fierce Biotech

Chugai Pharmabody Research

Flag link:

Roche Sees ‘No Urgency’ to Buy Rest of Chugai, CFO Says

Roche Sees ‘No Urgency’ to Buy Rest of Chugai, CFO Says

Bloomberg

Flag link:

Roche Said to Have Decided Against Bid for Rest of Chugai

Roche Said to Have Decided Against Bid for Rest of Chugai

Bloomberg

Flag link:

[video] Is a Roche-Chugai merger on the cards?

[video] Is a Roche-Chugai merger on the cards?

CNBC

Flag link:

Pages